Palisade Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Palisade Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,698	Closed	-$652K	–	435
2017 Q2	$652K	Sell	11,698 -1,000	-8%	-$54.4K	0.02%	361
2017 Q1	$691K	Sell	12,698 -2,450	-16%	-$134K	0.03%	345
2016 Q4	$885K	Buy	15,148 +1,677	+12%	+$91.7K	0.03%	341
2016 Q3	$726K	Buy	13,471 +9,750	+262%	+$626K	0.03%	456
2016 Q2	$274K	Hold	3,721	–	–	0.01%	504
2016 Q1	$238K	Hold	3,721	–	–	0.01%	511
2015 Q4	$256K	Sell	3,721 -119	-3%	-$7.86K	0.01%	503
2015 Q3	$227K	Buy	+3,840	New	+$244K	0.01%	503
2013 Q3	–	Sell	-12,098	Closed	-$541K	–	442
2013 Q2	$541K	Buy	+12,098	New	+$525K	0.02%	374

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Palisade Capital Management's BMY Position: Q3 2017 in Review

Palisade Capital Management sold out of Bristol-Myers Squibb (BMY) in Q3 2017, closing a stake of 11,698 shares — an estimated $652K sold.

Palisade Capital Management first reported a position in BMY in Q2 2013 and held it in 9 quarters. The position peaked at $885K in Q4 2016. 1,641 funds tracked by Wall St. Rank hold BMY as of Q3 2017.

Palisade Capital Management reported no remaining Bristol-Myers Squibb position as of Q3 2017 after selling out during the quarter.
Palisade Capital Management sold 11,698 Bristol-Myers Squibb shares in Q3 2017, an estimated $652K.
Palisade Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 9 quarters.
Palisade Capital Management's Bristol-Myers Squibb position peaked at $885K in Q4 2016.
1,641 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2017.

Based on Palisade Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.